Theralase Technologies Inc TLTFF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLTFF is a good fit for your portfolio.
News
-
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
-
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
-
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
-
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
-
Rutherrin(R) Increases Efficacy of Chemotherapy
-
Ruvidar(TM) Enhances Efficacy of Cancer Drug
-
Theralase(R) Successfully Destroys Lung Cancer
-
Theralase(R) Technology Effective in Virus Inactivation
Trading Information
- Previous Close Price
- $0.12
- Day Range
- $0.13–0.13
- 52-Week Range
- $0.10–0.23
- Bid/Ask
- $0.10 / $0.13
- Market Cap
- $31.57 Mil
- Volume/Avg
- 4,477 / 46,004
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 37.70
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 14
- Website
- https://www.theralase.com
Valuation
|
Metric
|
TLTFF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 37.70 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TLTFF
|
|---|---|
Quick Ratio | 0.67 |
Current Ratio | 1.53 |
Interest Coverage | −154.20 |
Quick Ratio
TLTFF
Profitability
|
Metric
|
TLTFF
|
|---|---|
Return on Assets (Normalized) | −120.43% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −171.91% |
Return on Assets
TLTFF
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Jjdnfhphm | Jmychlx | $183.1 Bil | |||
| Stryker Corp
SYK
| Lghqyzqb | Fns | $126.3 Bil | |||
| Boston Scientific Corp
BSX
| Cnlgqsk | Qcqxljs | $110.1 Bil | |||
| Medtronic PLC
MDT
| Bzhlhvvr | Zrtlc | $100.9 Bil | |||
| Edwards Lifesciences Corp
EW
| Qrsmbnch | Qtsmgnl | $37.6 Bil | |||
| DexCom Inc
DXCM
| Gczlpkbkhv | Zhwy | $25.6 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Jgdyqnvp | Pstsyvy | $24.1 Bil | |||
| Steris PLC
STE
| Dfgzspty | Hmztzm | $23.0 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Gmhgcpbw | Lgb | $22.9 Bil | |||
| Align Technology Inc
ALGN
| Gsmbhlj | Gprzgd | $16.6 Bil |